A Comprehensive Monograph on Spironolactone (DB00421): From Aldosterone Antagonism to Anti-androgen Therapy

1.0 Introduction and Drug Profile

1.1 Overview of Spironolactone

Spironolactone is a synthetic 17-spironolactone corticosteroid that has occupied a unique and expanding role in therapeutics for over six decades.[1] Developed in 1957 and receiving its initial approval from the U.S. Food and Drug Administration (FDA) in 1960, its clinical journey began as a potassium-sparing diuretic for the management of hypertension and edematous states.[2] However, its multifaceted pharmacological profile has since established it as a cornerstone therapy in a diverse range of medical specialties. The drug is fundamentally characterized by a dual identity: it functions as a potent, competitive antagonist of the mineralocorticoid receptor (MR), thereby blocking the effects of aldosterone, and as a nonselective hormonal agent with clinically significant anti-androgenic properties.[5]

This dual mechanism of action underpins its broad therapeutic utility. In cardiology and nephrology, its primary role as an aldosterone antagonist is leveraged to treat severe heart failure, resistant hypertension, and fluid retention (edema) associated with hepatic or renal disease.[3] In endocrinology and dermatology, its secondary anti-androgenic effects are harnessed for the off-label management of conditions driven by androgen excess, such as acne vulgaris, hirsutism in women, and symptoms associated with polycystic ovary syndrome (PCOS).[3] This report will provide a comprehensive examination of spironolactone, exploring its chemical nature, its complex pharmacodynamics and pharmacokinetics, its full spectrum of clinical applications, detailed dosing and administration guidelines, and a robust safety profile essential for its judicious use in clinical practice. As a small molecule drug included on the World Health Organization's List of Essential Medicines, spironolactone's global importance and clinical versatility are well-established, warranting a thorough and nuanced understanding by healthcare professionals.[3]

1.2 Identification and Physicochemical Properties

A precise and unambiguous identification of a pharmaceutical agent is fundamental to its safe and effective use. This section consolidates the nomenclature, structural data, and physical characteristics of spironolactone.

The chemical architecture of spironolactone offers a clear explanation for its pharmacological activities. Its core structure is a steroid backbone (17α-pregn-4-ene), which bears a strong resemblance to endogenous steroid hormones, including aldosterone, androgens (like testosterone), and progesterone.[1] This structural mimicry is the molecular basis for its ability to competitively bind to the receptors for these hormones. The specific modifications to this steroid nucleus—namely the addition of a

γ-lactone ring at the C17 position and an acetylsulfanyl group at the 7α position—are what confer its distinct profile as a potent aldosterone antagonist with secondary anti-androgenic activity. This inherent structural similarity explains not only its therapeutic efficacy at the mineralocorticoid receptor but also its predictable "off-target" binding to androgen and progesterone receptors, which is the source of both its utility in dermatological conditions and its common hormonal side effects.[3] Thus, the drug's entire clinical profile can be traced back to these fundamental structural features.

The following table provides a consolidated summary of spironolactone's key identifiers and physicochemical properties for reference.

Property	Details	References
Generic Name	Spironolactone	3
Common Brand Names (US)	Aldactone, CaroSpir	3
DrugBank ID	DB00421	2
CAS Number	52-01-7	2
Synonyms	SC-9420, NSC 150399, Aldace, Almatol, Spiractin	1
Molecular Formula	C24​H32​O4​S	18
Molecular Weight	Approx. 416.57 g/mol	18
Chemical Description	A steroid lactone; 17α-pregn-4-ene-21,17-carbolactone substituted with an oxo group at position 3 and an α-acetylsulfanyl group at position 7.	2
IUPAC Name	S-phenanthrene-17,2'-oxolane]-7-yl] ethanethioate	2
InChIKey	LXMSZDCAJNLERA-ZHYRCANASA-N	2
Physical Description	Light cream-colored to light tan crystalline powder or solid.	2
Odor	Mild mercaptan-like odor	2
Melting Point	207–208 °C	22
Solubility	Practically insoluble in water; soluble in alcohol, chloroform, and ethyl acetate.	2

2.0 Clinical Pharmacology

2.1 Pharmacodynamics

The pharmacodynamic profile of spironolactone is characterized by its dual action as a mineralocorticoid receptor antagonist and an anti-androgen. These distinct, yet structurally related, mechanisms account for its wide-ranging therapeutic applications and its characteristic adverse effect profile.

2.1.1 Mechanism of Action: Mineralocorticoid Receptor Antagonism

Spironolactone's primary mechanism of action is as a specific, competitive antagonist of aldosterone at the mineralocorticoid receptor (MR).[1] Its principal site of action is the aldosterone-dependent sodium-potassium exchange site located in the distal convoluted renal tubules and collecting ducts of the nephron.[3] In these segments of the kidney, aldosterone normally promotes the reabsorption of sodium and water from the tubular fluid back into the bloodstream, in exchange for potassium, which is secreted into the urine.

By competitively binding to the MR, spironolactone and its active metabolites prevent aldosterone from exerting its effects. This blockade inhibits the reabsorption of sodium and, consequently, water, leading to a diuretic effect (natriuresis).[3] Simultaneously, the drug inhibits the secretion of potassium into the urine, resulting in potassium retention. This latter effect is the basis for its classification as a "potassium-sparing" diuretic.[3] This combined diuretic and potassium-sparing action is fundamental to its efficacy in treating hypertension and edema.[3]

Beyond its renal effects, aldosterone antagonism has important systemic cardiovascular benefits. Chronic aldosterone excess is known to promote pathological processes such as myocardial and vascular fibrosis, vascular remodeling, endothelial dysfunction, and inflammation.[5] By blocking these effects, spironolactone helps to mitigate the adverse cardiac remodeling that is a hallmark of progressive heart failure, providing a key component of its mortality benefit in this condition.[5]

2.1.2 Anti-androgenic and Other Hormonal Effects

Spironolactone is a nonselective antagonist, meaning its structural similarity to other steroid hormones allows it to interact with other receptor types.[5] Most significantly, it functions as a direct antagonist of the androgen receptor (AR), where it competes with endogenous androgens like testosterone and its more potent metabolite, dihydrotestosterone (DHT).[3] This blockade of androgen action at target tissues, such as the sebaceous glands and hair follicles, is the primary mechanism underlying its off-label efficacy in treating androgen-dependent dermatological conditions, including acne vulgaris, hirsutism, and female pattern hair loss.[3]

In addition to direct receptor blockade, spironolactone may also weakly inhibit enzymes involved in androgen biosynthesis, such as steroid 17α-hydroxylase (CYP17A1), further contributing to a reduction in androgen levels.[14] The drug also exhibits weak progestogenic activity and has a low affinity for glucocorticoid and estrogen receptors.[3]

This non-selectivity creates a clinical paradox where the same mechanism of action can be either therapeutic or adverse, depending entirely on the patient and the clinical indication. For a woman being treated for hirsutism or acne, the blockade of the androgen receptor is the desired therapeutic goal, leading to reduced sebum production and decreased hair growth.[28] However, for a male patient being treated for heart failure, this same mechanism of androgen receptor antagonism is responsible for a constellation of common and often treatment-limiting adverse effects, including gynecomastia (breast enlargement), decreased libido, and erectile dysfunction.[5] This duality highlights the critical trade-offs in spironolactone therapy and was a primary driver for the development of more selective mineralocorticoid receptor antagonists, such as eplerenone, which lack significant affinity for androgen and progesterone receptors and thus avoid these hormonal side effects.[26]

2.2 Pharmacokinetics

The clinical effects and dosing schedule of spironolactone are best understood through its pharmacokinetic profile, particularly its extensive metabolism into multiple active compounds. Spironolactone itself functions as a prodrug, with its metabolites being largely responsible for its sustained therapeutic activity.[14]

2.2.1 Absorption, Distribution, Metabolism, and Excretion (ADME)

• Absorption: Spironolactone is rapidly absorbed from the gastrointestinal tract following oral administration.[23] Its bioavailability is significantly influenced by the presence of food. Co-administration with a meal can increase the area under the curve (AUC) of the unmetabolized parent drug by nearly 100%, although the clinical significance of this finding is not fully established.[23] To ensure consistent exposure, patients should be advised to take the medication in a routine manner with respect to meals.[8] Peak plasma concentrations ( Cmax​) of the parent drug are typically reached within 1.4 to 2.6 hours post-dose.[3]
• Distribution: Spironolactone and its metabolites are highly bound to plasma proteins, with over 90% bound to albumin and α1​-acid glycoprotein.[14] This extensive protein binding limits its volume of distribution. Canrenone, a major active metabolite, is known to be distributed into breast milk.[37]
• Metabolism: The drug undergoes rapid and extensive first-pass metabolism, primarily in the liver.[14] The metabolic pathways are complex and can be broadly divided into two categories: those in which the sulfur moiety at the C7 position is removed (dethioacetylation), leading to the formation of canrenone, and those in which the sulfur is retained and modified, leading to sulfur-containing metabolites.[3] The primary sulfur-containing metabolites are 7α-thiomethylspironolactone (TMS) and 6β-hydroxy-7α-thiomethylspironolactone (HTMS).[23]
• Excretion: The metabolites of spironolactone are eliminated from the body primarily through renal excretion into the urine, with a secondary route of excretion into the bile and feces.[14]

2.2.2 Profile of Active Metabolites

The sustained clinical activity of spironolactone is attributable to its active metabolites, which have significantly longer half-lives than the parent compound. The parent drug, spironolactone, has a very short half-life of approximately 1.4 hours.[14] In contrast, its major active metabolites have terminal half-lives that are an order of magnitude longer: canrenone at approximately 16.5 hours, TMS at 13.8 hours, and HTMS at 15.0 hours.[14] This stark difference explains why a drug with a short-lived parent compound can be dosed once or twice daily and still maintain a prolonged pharmacodynamic effect.

These metabolites also contribute differentially to the overall therapeutic effect. Studies suggest that the sulfur-containing metabolite, TMS, is responsible for approximately 80% of the drug's potassium-sparing (antimineralocorticoid) effect, while canrenone accounts for the remaining 10% to 25%.[14] The following table summarizes and contrasts the key pharmacokinetic parameters of spironolactone and its principal active metabolites.

Compound	Time to Peak Concentration (Tmax​)	Terminal Half-Life (t1/2​)	Plasma Protein Binding	Primary Role
Spironolactone (Parent Drug)	2.6 hours	~1.4 hours	>90%	Prodrug; limited direct activity
Canrenone (C)	4.3 hours	~16.5 hours	>90%	Active metabolite; contributes to antimineralocorticoid and anti-androgenic effects
7α-thiomethylspironolactone (TMS)	3.2 hours	~13.8 hours	>90%	Primary active metabolite for antimineralocorticoid (potassium-sparing) effect
6β-hydroxy-7α-thiomethylspironolactone (HTMS)	5.1 hours	~15.0 hours	>90%	Active metabolite
Data synthesized from sources.14

3.0 Therapeutic Indications and Clinical Efficacy

Spironolactone's unique dual pharmacology has led to its approval and widespread use for a variety of cardiovascular, renal, and endocrine disorders. Furthermore, its anti-androgenic properties have established it as a valuable off-label agent in dermatology and gynecology.

3.1 Approved Cardiovascular and Renal Indications

3.1.1 Heart Failure with Reduced Ejection Fraction (HFrEF)

Spironolactone is a guideline-directed medical therapy for patients with symptomatic heart failure (New York Heart Association Class II-IV) and a reduced left ventricular ejection fraction (LVEF≤35%).[3] It is indicated to increase survival, manage edema, and reduce the need for hospitalization for heart failure, and it is typically administered as an adjunct to other standard therapies such as ACE inhibitors or ARBs, and beta-blockers.[3]

The cornerstone of evidence for its use in this population is the landmark Randomized Aldactone Evaluation Study (RALES). This trial, published in 1999, randomized patients with severe HFrEF to receive either low-dose spironolactone (25 mg daily) or placebo in addition to standard therapy. The trial was terminated early by its data and safety monitoring board due to the overwhelming benefit observed in the treatment group, which demonstrated a 30% relative risk reduction in all-cause mortality compared to placebo.[4] Spironolactone also significantly reduced the risk of death from progressive heart failure and the rate of hospitalization for cardiac causes.[23]

More recently, the CLEAR SYNERGY trial investigated the use of spironolactone after a myocardial infarction and found that it reduced the risk of developing new or worsening heart failure, although it did not significantly impact the rate of death or other major cardiovascular events in this specific setting.[41]

The role of spironolactone in heart failure with preserved ejection fraction (HFpEF) is less clear and remains an area of active investigation. Aldosterone-mediated fibrosis is implicated in the pathophysiology of diastolic dysfunction, providing a strong rationale for its use.[25] However, clinical trials, including the large TOPCAT trial, have yielded mixed results. While some analyses suggest spironolactone may reduce heart failure hospitalizations and improve markers of diastolic function in certain subgroups of HFpEF patients, a definitive mortality benefit has not been consistently demonstrated across the entire HFpEF population.[25]

3.1.2 Hypertension

Spironolactone is approved as an add-on therapy for the treatment of hypertension in patients whose blood pressure is not adequately controlled with other antihypertensive agents.[3] It is considered a preferred agent for the management of resistant hypertension, which is defined as high blood pressure that remains above goal despite the use of three or more antihypertensive drugs of different classes, including a diuretic.[5] Its efficacy in this setting is particularly pronounced in patients with low-renin or aldosterone-driven hypertension.[16] The blood pressure-lowering effect is achieved through both its diuretic action, which reduces plasma volume, and its ability to counteract the direct effects of aldosterone on vascular stiffness and remodeling.[3]

3.1.3 Edematous Conditions

Spironolactone is indicated for the management of edema (fluid retention) in conditions characterized by secondary hyperaldosteronism, where the body produces excess aldosterone in response to fluid and sodium shifts.[23] This includes:

• Hepatic Cirrhosis with Ascites: It is used to manage ascites (fluid accumulation in the abdomen) and edema in patients with cirrhosis, particularly when fluid and sodium restriction alone are insufficient.[3]
• Nephrotic Syndrome: It is indicated for edema associated with nephrotic syndrome when the primary treatment of the underlying kidney disease, fluid and sodium restriction, and the use of other diuretics fail to produce an adequate response.[3]

In these settings, spironolactone's ability to directly counteract the high levels of aldosterone makes it a logical and effective therapeutic choice.[23] Patient-reported outcomes are variable, with many experiencing significant relief from fluid overload, while others may discontinue treatment due to adverse effects like electrolyte disturbances or muscle cramping.[46]

3.2 Approved Endocrine Indications

3.2.1 Primary Hyperaldosteronism

Spironolactone plays a central role in the diagnosis and management of primary hyperaldosteronism (Conn's syndrome), a condition where the adrenal glands produce excessive amounts of aldosterone independent of the renin-angiotensin system.[3]

• Diagnosis: A therapeutic trial of spironolactone can be used as a diagnostic tool. If administration of the drug corrects hypokalemia and lowers blood pressure, it provides presumptive evidence of primary hyperaldosteronism.[3]
• Treatment: For patients with a discrete, aldosterone-producing adrenal adenoma, spironolactone is used as a short-term preoperative treatment to control blood pressure and correct electrolyte imbalances before surgical removal of the tumor.[3] For patients who are not candidates for surgery, or for those with bilateral adrenal hyperplasia (idiopathic hyperaldosteronism), spironolactone is used as a long-term maintenance therapy to manage the effects of chronic aldosterone excess.[3]

3.3 Prominent Off-Label Applications

The anti-androgenic properties of spironolactone have led to its extensive and evidence-supported use in several off-label indications, primarily in women.

3.3.1 Dermatological Uses: Acne Vulgaris and Hirsutism

• Acne Vulgaris: Spironolactone is widely recognized by dermatologists as a highly effective off-label treatment for hormonal acne in adult women.[3] It is particularly useful for persistent or late-onset acne that is often localized to the lower face, jawline, and neck, and which may flare with the menstrual cycle.[29] By blocking androgen receptors in the skin, it reduces sebum (oil) production, a key factor in the development of acne.[5] It serves as an important non-antibiotic alternative, which is increasingly relevant in an era of antibiotic stewardship.[49] Clinical studies and retrospective reviews have demonstrated significant efficacy, with improvement ranging from a 50% to 100% reduction in acne lesions.[50] Patients typically notice a decrease in oiliness and breakouts within a few weeks, although the maximal therapeutic effect may take three to six months to become apparent.[51] Due to its feminizing side effects, it is not recommended for the treatment of acne in men.[49]
• Hirsutism: Spironolactone is an effective treatment for hirsutism, the excessive growth of coarse, dark hair in a male-like pattern in women.[3] Its efficacy stems from its dual anti-androgenic actions: blocking androgen receptors at the hair follicle and reducing the production of androgens like testosterone.[32] Noticeable regression in hair growth, density, and diameter typically occurs within two to six months of initiating therapy.[32] For enhanced efficacy and to regulate menstrual cycles, which can become irregular with spironolactone monotherapy, it is often prescribed in combination with an oral contraceptive pill.[31]

3.3.2 Polycystic Ovary Syndrome (PCOS)

PCOS is a common endocrine disorder in women of reproductive age, frequently characterized by hyperandrogenism (high levels of androgens).[57] Spironolactone is used off-label to directly target and manage the cutaneous manifestations of this hyperandrogenism, including hirsutism, acne, and androgenic alopecia (female pattern hair loss).[57] By blocking the effects of excess androgens on the skin and hair follicles, it can provide significant symptomatic relief for patients with PCOS.[58] It is often considered a second-line therapy, added after a trial of oral contraceptives, or used in patients for whom estrogen-containing contraceptives are contraindicated.[61]

4.0 Dosage, Administration, and Formulations

4.1 Available Formulations and Strengths

Spironolactone is commercially available in two oral formulations, providing flexibility for administration across different patient populations:

• Oral Tablets: This is the most common formulation, available both as a generic medication and under the brand name Aldactone. Standard tablet strengths in the United States are 25 mg, 50 mg, and 100 mg.[8] Tablets are often scored, allowing for dose adjustments.
• Oral Suspension: A liquid formulation is available under the brand name CaroSpir, typically supplied at a concentration of 25 mg per 5 mL.[8] This formulation is particularly useful for pediatric patients and for adults who have difficulty swallowing tablets (dysphagia).

4.2 Dosing and Titration by Indication

The appropriate dosage of spironolactone varies substantially depending on the clinical indication, the patient's renal function, and serum potassium levels. Doses can range from as low as 12.5 mg every other day to as high as 400 mg per day. The following table synthesizes dosing recommendations from multiple clinical sources for both approved and common off-label uses. It is imperative that therapy is individualized and that patients are monitored appropriately, especially when initiating therapy or titrating the dose.

Indication	Patient Population	Typical Starting Dose	Dose Range & Titration	Maximum Daily Dose	Key Considerations & References
Heart Failure (HFrEF)	Adults with eGFR >50 mL/min/1.73 m2 and K+ ≤ 5.0 mEq/L	12.5 mg to 25 mg once daily	Titrate to 25 mg or 50 mg once daily as tolerated. Reduce to 12.5 mg daily or every other day if hyperkalemia develops.	50 mg	Initiate at lower dose (e.g., 12.5 mg every other day) if eGFR is 30-50 mL/min/1.73 m2. 5
Hypertension	Adults	25 mg to 50 mg once daily	Titrate at 2-week intervals. Can be given in single or divided doses.	100 mg	Doses >100 mg/day generally do not provide additional blood pressure reduction. 3
Edema (Cirrhosis, Nephrotic Syndrome)	Adults	100 mg per day (single or divided doses)	Titrate slowly over at least 5 days.	200 mg (Nephrotic Syndrome) to 400 mg (Cirrhosis)	Initiate therapy in a hospital setting for patients with hepatic impairment. 3
Primary Hyperaldosteronism	Adults	100 mg to 400 mg per day	Used preoperatively or for long-term maintenance at the lowest effective dose.	400 mg	Dose is titrated to normalize blood pressure and potassium levels. 3
Acne Vulgaris (Off-label)	Adult Females	50 mg to 100 mg once daily	Can be started at 25-50 mg daily and titrated up based on response and tolerability.	200 mg	Improvement may take 3-6 months. Routine potassium monitoring in healthy young women is often not required. 29
Hirsutism (Off-label)	Adult Females	50 mg to 100 mg daily (often in divided doses)	Titrate up to a target dose of 100-200 mg daily.	200 mg	Full effect may take ≥6 months. Often combined with oral contraceptives. 31
PCOS Symptoms (Off-label)	Adult Females	50 mg daily	Titrate based on symptoms (hirsutism, acne) to a typical range of 100-200 mg daily.	200 mg	Effective contraception is essential due to teratogenic risk. 61

4.3 Key Administration Considerations

• Effect of Food: As food significantly increases the absorption of spironolactone, it is crucial for patients to maintain consistency in administration relative to meals (i.e., always take with food or always take without food) to ensure stable drug levels.[8] Taking the medication with food can also help to minimize potential gastrointestinal side effects such as nausea.[10]
• Timing of Doses: Due to its diuretic effect, spironolactone should be administered in the morning to avoid nocturia (waking at night to urinate). If a twice-daily regimen is prescribed, the second dose should be taken in the late afternoon, generally no later than 4 p.m..[10]
• Duration of Therapy: The duration of treatment is highly dependent on the indication. For chronic conditions such as heart failure and hypertension, therapy is typically lifelong.[39] For dermatological uses like acne and hirsutism, treatment often continues for one to several years, with periodic re-evaluation to determine if the medication is still needed.[29]

5.0 Safety Profile and Risk Management

The use of spironolactone requires a thorough understanding of its safety profile, which is dominated by the risks of hyperkalemia and hormonal side effects. Careful patient selection, monitoring, and education are essential to mitigate these risks.

5.1 Adverse Drug Reactions

• Hyperkalemia (High Potassium Levels): This is the most significant and potentially life-threatening adverse effect of spironolactone therapy.[10] The risk is substantially elevated in patients with underlying renal impairment, elderly patients, individuals with diabetes, and those taking concomitant medications that also increase serum potassium levels.[5] Symptoms of hyperkalemia can be nonspecific and include nausea, fatigue, muscle weakness, a tingling sensation, or can be severe, leading to life-threatening cardiac arrhythmias, including bradycardia and cardiac arrest.[12]
• Hormonal/Anti-androgenic Effects: Due to its non-selective binding to steroid hormone receptors, spironolactone frequently causes hormonal side effects. In men, gynecomastia (painful or painless breast enlargement) is the most common adverse reaction, with an incidence that is dependent on both the dose and duration of therapy.[5] Other anti-androgenic effects in men include decreased libido and erectile dysfunction.[5] In women, the most common hormonal side effect is menstrual irregularity, including spotting, amenorrhea, or changes in cycle length.[5] Breast tenderness can occur in both sexes.[33]
• Renal and Electrolyte Effects: As a diuretic, spironolactone can lead to volume depletion, causing symptomatic hypotension (especially orthostatic), dizziness, and dehydration. This can, in turn, lead to a reversible decline in renal function.[9] Other electrolyte abnormalities, such as hyponatremia (low sodium), can also occur.[12]
• General Side Effects: More common, less severe side effects include dizziness, drowsiness, headache, gastrointestinal disturbances (nausea, vomiting, diarrhea), and muscle or leg cramps.[9]
• Rare but Serious Reactions: Although infrequent, severe and potentially fatal skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported.[9] Hepatotoxicity, while rare, can also occur.[75]

5.2 Contraindications and Black Box Warning

• Contraindications: Spironolactone is absolutely contraindicated in patients with pre-existing hyperkalemia, Addison's disease (adrenal insufficiency, which itself causes hyperkalemia), anuria (inability to produce urine), and significant renal impairment.[8] Concomitant use with eplerenone, another mineralocorticoid receptor antagonist, is also contraindicated due to the high risk of severe hyperkalemia.[8]
• Black Box Warning: The prescribing information for spironolactone in the United States includes a boxed warning from the FDA. This warning states that the drug was found to be a tumorigen in chronic toxicity studies conducted in rats, causing benign adenomas of endocrine organs and the liver. The warning emphasizes that spironolactone should be used only for its specified indications and that unnecessary use should be avoided.[36] While a causal relationship between spironolactone and breast cancer in humans has not been established, and some studies have refuted this link, this warning remains a point of caution and discussion with patients, particularly those with a strong family history of breast malignancy.[31]

5.3 Drug and Food Interactions

5.3.1 Drug Interactions

The risk of hyperkalemia is significantly amplified when spironolactone is co-administered with other drugs that affect potassium homeostasis. These interactions are of high clinical significance.

Interacting Drug/Class	Mechanism of Interaction	Clinical Consequence	Management Strategy
ACE Inhibitors (e.g., lisinopril, ramipril)	Both drug classes reduce potassium excretion.	High risk of severe, life-threatening hyperkalemia.	Use with extreme caution. Start with low doses of both agents. Monitor potassium and renal function frequently, especially upon initiation and dose changes.
Angiotensin II Receptor Blockers (ARBs) (e.g., losartan, valsartan)	Both drug classes reduce potassium excretion.	High risk of severe, life-threatening hyperkalemia.	Same as for ACE inhibitors. Use with extreme caution and monitor closely.
Potassium Supplements & Other Potassium-Sparing Diuretics (e.g., amiloride, triamterene, eplerenone)	Additive potassium-retaining effects.	Very high risk of severe hyperkalemia.	Concomitant use is generally contraindicated. Discontinue potassium supplements before starting spironolactone.
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) (e.g., ibuprofen, naproxen, celecoxib)	Can reduce the diuretic and antihypertensive effects of spironolactone. Can also impair renal function and reduce potassium excretion.	Increased risk of hyperkalemia and acute kidney injury. Reduced therapeutic effect of spironolactone.	Avoid chronic concomitant use if possible. If necessary, monitor renal function and potassium levels closely.
Trimethoprim (often in combination with sulfamethoxazole)	Trimethoprim has a potassium-sparing effect similar to amiloride.	High risk of severe hyperkalemia.	Avoid combination if possible, especially in elderly patients or those with renal impairment.
Lithium	Spironolactone can reduce the renal clearance of lithium.	Increased lithium levels and risk of lithium toxicity.	Avoid combination if possible. If necessary, monitor lithium levels frequently and adjust lithium dose.
Digoxin	Spironolactone can increase the half-life of digoxin. It can also interfere with certain digoxin assays, giving falsely elevated readings.	Increased digoxin levels and risk of digitalis toxicity.	Monitor for clinical signs of digoxin toxicity. Use digoxin assays that are not affected by spironolactone metabolites if available.
Data synthesized from sources.12

5.3.2 Food Interactions

To mitigate the risk of hyperkalemia, patients taking spironolactone should be counseled to avoid or limit their intake of foods that are very high in potassium. This includes certain fruits (bananas, oranges, avocados), vegetables (potatoes, spinach), and pulses (lentils, beans).[10] Critically, patients must be advised to avoid potassium-containing salt substitutes (e.g., Lo-Salt, Nu-Salt), as these products can contribute a significant potassium load and precipitate dangerous hyperkalemia.[10]

5.4 Monitoring and Management of Hyperkalemia

The clinical approach to monitoring for hyperkalemia with spironolactone therapy is not uniform and demonstrates a clear dichotomy based on the patient population being treated. This divergence in practice is based on the vastly different baseline risks between the typical cardiovascular patient and the typical dermatologic patient.

For the population treated for cardiovascular disease—who are often elderly, have baseline chronic kidney disease or diabetes, and are frequently on concomitant ACE inhibitors or ARBs—the risk of hyperkalemia is substantial and well-documented.[86] The real-world data following the publication of the RALES trial starkly illustrated this danger, showing a significant increase in hospitalizations and mortality from hyperkalemia when the drug was applied to a broader, higher-risk population than was studied in the clinical trial.[4] For these patients, diligent and routine monitoring of serum potassium and renal function is mandatory. Monitoring should occur within the first week of initiation, after any dose increase, and periodically thereafter for the duration of therapy.[5]

In stark contrast, for the population of young, healthy women without comorbidities who are treated with low-to-moderate doses of spironolactone for dermatological conditions like acne, the risk of clinically significant hyperkalemia is very low. Multiple large retrospective studies and systematic reviews have concluded that hyperkalemia in this group is rare, and when it does occur, it is invariably mild and clinically insignificant.[14] This evidence has led to a shift in clinical practice guidelines from organizations like the American Academy of Dermatology, which now suggest that routine potassium monitoring may be unnecessary for this specific patient population.[14] This approach reduces the cost and logistical burden of treatment, potentially improving patient access and adherence. Therefore, the decision to monitor potassium levels must be individualized, based on a careful assessment of the patient's age, renal function, comorbidities, and concomitant medications.

6.0 Considerations in Special Populations

6.1 Geriatric Use

The use of spironolactone in elderly patients requires significant caution. While studies have not shown that the drug is inherently less effective in this population, elderly patients are at a substantially higher risk for adverse events, primarily due to the higher prevalence of age-related decline in renal function.[39] As renal function decreases, the ability to excrete potassium is impaired, markedly increasing the risk of developing hyperkalemia.[5] Real-world, population-based studies conducted after the RALES trial revealed a dramatic increase in hospitalizations and mortality from hyperkalemia among older patients who began taking spironolactone.[86] This highlights a critical gap between the highly selected, closely monitored populations in clinical trials and the broader, more vulnerable population seen in general practice. Therefore, in geriatric patients, it is prudent to initiate therapy at the lowest possible dose (e.g., 12.5 mg daily or every other day), titrate slowly, and maintain a high index of suspicion for adverse effects with diligent monitoring of renal function and electrolytes.[86]

6.2 Pediatric Use

While safety and effectiveness have not been formally established through large-scale trials, spironolactone is used off-label in pediatric patients, from infants to adolescents, for several conditions.[8] Common uses include the management of edema associated with bronchopulmonary dysplasia (BPD) in infants, congenital heart disease, and nephrotic syndrome, as well as for hypertension.[88] Dosing is typically based on body weight, with initial doses commonly in the range of 1 to 3 mg/kg/day, administered in divided doses.[88] For administration to young children who cannot swallow tablets, a liquid suspension can be compounded by a pharmacy, or tablets can be crushed and mixed with a small amount of soft food or syrup.[89] Parents and caregivers should be counseled on proper administration techniques, potential side effects such as dizziness or gastrointestinal upset, and the importance of adhering to scheduled blood work to monitor electrolytes.[75]

6.3 Use in Pregnancy and Lactation

• Pregnancy: Spironolactone is generally not recommended for use during pregnancy. Due to its anti-androgenic mechanism of action, there is a theoretical but significant risk of adverse effects on the sexual differentiation of a male fetus, potentially leading to feminization of the external genitalia.[5] Animal studies have demonstrated such effects.[5] Therefore, women of childbearing potential who are taking spironolactone must be advised to use effective contraception to prevent pregnancy.[31]
• Lactation: Spironolactone is considered compatible with breastfeeding.[74] The parent drug is poorly excreted into breast milk. Its major active metabolite, canrenone, is present in breast milk, but only in very small amounts.[37] The estimated daily dose that an infant would receive is approximately 0.2% of the mother's weight-adjusted dose, which is considered clinically insignificant.[37] Studies and case reports of mothers breastfeeding while taking spironolactone have not reported any adverse effects in their infants.[37]

7.0 Regulatory and Commercial Information

7.1 Regulatory Approval History

• U.S. Food and Drug Administration (FDA): Spironolactone was first approved by the FDA in 1960, initially for the treatment of hypertension.[2] Its role in cardiovascular medicine was significantly expanded following the positive results of the RALES trial in 1999, which firmly established its indication for improving mortality in patients with severe heart failure with reduced ejection fraction.[4]
• European Medicines Agency (EMA): Spironolactone has been an established and widely used medication in the European Union for several decades.[77] Regulatory activity continues, with recent authorizations such as the one granted for Qaialdo, an oral suspension formulation, in May 2023 for the treatment of refractory edema.[16] This confirms its ongoing regulatory standing and therapeutic importance in Europe. EMA documentation also reflects its approval for veterinary use, specifically for treating congestive heart failure in dogs.[93]

7.2 Global Brand Names and Availability

Spironolactone is available worldwide as a generic medication and is marketed under a vast number of brand names. Aldactone is the most universally recognized trade name.[2]

A notable aspect of its global availability is the prevalence of fixed-dose combination products, particularly outside of the United States. These products combine spironolactone with another diuretic, most commonly a thiazide (e.g., hydrochlorothiazide, marketed as Aldactazide) or a loop diuretic (e.g., furosemide, marketed as Lasilactone).[10] These combinations aim to provide a more potent diuretic effect while mitigating the potassium loss associated with thiazide or loop diuretics alone. The following table lists a selection of international brand names to illustrate its global presence and the commonality of combination formulations.

Brand Name	Active Ingredient(s)	Selected Countries/Regions
Aldactone	Spironolactone	Worldwide (e.g., Europe, Asia, South America, Australia)
Aldactazine	Spironolactone + Altizide	France, Portugal, Belgium
Aldactazide	Spironolactone + Hydrochlorothiazide	Canada, Italy, Pakistan, Venezuela
Aldactide	Spironolactone + Hydroflumethiazide	United Kingdom, India, Taiwan
Lasilactone	Spironolactone + Furosemide	United Kingdom, India, Mexico, Argentina
Verospiron	Spironolactone	Eastern Europe (e.g., Hungary, Poland, Romania), Russia
Spirix	Spironolactone	Nordic Countries (e.g., Finland, Norway, Denmark)
Espironolactona	Spironolactone	Spain, Portugal, Latin America (e.g., Brazil, Chile, Argentina)
Aldactone-A	Spironolactone	Japan, Argentina, Mexico
Carpiaton	Spironolactone	Indonesia
Data synthesized from sources.2

8.0 Conclusion

Spironolactone is a medication of remarkable versatility, whose clinical utility has expanded far beyond its original indication as a diuretic. Its dual identity as a mineralocorticoid receptor antagonist and an anti-androgen has established it as an indispensable tool in the management of a wide array of conditions, from life-threatening heart failure to chronic dermatological disorders.

The primary pharmacological action—competitive antagonism of aldosterone—provides robust, evidence-based benefits in reducing mortality in HFrEF, controlling resistant hypertension, and managing complex edematous states. Its secondary action—blockade of the androgen receptor—offers a highly effective, non-antibiotic option for women suffering from hormonal acne and hirsutism.

However, this therapeutic breadth is accompanied by a complex safety profile that demands careful clinical judgment. The same hormonal effects that are beneficial in one context can be treatment-limiting adverse events in another. The risk of hyperkalemia, its most serious adverse effect, varies dramatically across patient populations, necessitating a nuanced, individualized approach to monitoring. For the elderly patient with multiple comorbidities, vigilant surveillance of potassium and renal function is paramount. For the young, healthy woman seeking treatment for acne, such intensive monitoring may be unnecessary.

After more than 60 years of clinical use, spironolactone remains a vital and effective medication. Its continued relevance is a testament to its unique mechanisms of action. A thorough understanding of its multifaceted pharmacology, its indication-specific dosing, and its population-dependent risks is essential for clinicians to harness its benefits while ensuring patient safety.

Works cited

1. Definition of spironolactone - NCI Drug Dictionary, accessed July 23, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/spironolactone
2. Spironolactone | C24H32O4S | CID 5833 - PubChem, accessed July 23, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Spironolactone
3. Spironolactone: Uses, Interactions, Mechanism of Action - DrugBank, accessed July 23, 2025, https://go.drugbank.com/drugs/DB00421
4. Spironolactone and chlorthalidone—old drugs, new uses—but ..., accessed July 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8875470/
5. Spironolactone - StatPearls - NCBI Bookshelf, accessed July 23, 2025, https://www.ncbi.nlm.nih.gov/books/NBK554421/
6. www.ncbi.nlm.nih.gov, accessed July 23, 2025, https://www.ncbi.nlm.nih.gov/books/NBK554421/#:~:text=Spironolactone%20is%20a%20medication%20used,receptor%20antagonist%20class%20of%20drugs.
7. Spironolactone: MedlinePlus Drug Information, accessed July 23, 2025, https://medlineplus.gov/druginfo/meds/a682627.html
8. Spironolactone: Uses, Dosage, Side Effects - Drugs.com, accessed July 23, 2025, https://www.drugs.com/spironolactone.html
9. Spironolactone oral tablet: Dosage, side effects, uses, and more - Medical News Today, accessed July 23, 2025, https://www.medicalnewstoday.com/articles/drugs-spironolactone-oral-tablet
10. About spironolactone - NHS, accessed July 23, 2025, https://www.nhs.uk/medicines/spironolactone/about-spironolactone/
11. Spironolactone: Side Effects, Uses, Dosage, and More - Healthline, accessed July 23, 2025, https://www.healthline.com/health/spironolactone-oral-tablet
12. Spironolactone (Aldactone, Carospir): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD, accessed July 23, 2025, https://www.webmd.com/drugs/2/drug-6288/spironolactone-oral/details
13. 7 Common Uses of Spironolactone - Verywell Health, accessed July 23, 2025, https://www.verywellhealth.com/spironolactone-uses-11678840
14. Spironolactone - Wikipedia, accessed July 23, 2025, https://en.wikipedia.org/wiki/Spironolactone
15. spironolactone (CHEBI:9241) - EMBL-EBI, accessed July 23, 2025, https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9241
16. spironolactone | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed July 23, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=2875
17. Spironolactone (NSC 150399, SC-9420, CAS Number: 52-01-7) | Cayman Chemical, accessed July 23, 2025, https://www.caymanchem.com/product/9000324/spironolactone
18. CAS Number 52-01-7 | Spironolactone - Spectrum Chemical, accessed July 23, 2025, https://www.spectrumchemical.com/cas/52-01-7
19. spironolactone | C24H32O4S - ChemSpider, accessed July 23, 2025, https://www.chemspider.com/Chemical-Structure.5628.html
20. Spironolactone | CAS 52-01-7 | SCBT - Santa Cruz Biotechnology, accessed July 23, 2025, https://www.scbt.com/p/spironolactone-52-01-7
21. Spironolactone (CAS 52-01-7) - Glentham Life Sciences, accessed July 23, 2025, https://www.glentham.com/en/products/product/GP5407/
22. Spironolactone 97.0-103.0 52-01-7 - Sigma-Aldrich, accessed July 23, 2025, https://www.sigmaaldrich.com/US/en/product/sigma/s3378
23. Aldactone - accessdata.fda.gov, accessed July 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/012151s062lbl.pdf
24. ALDACTONE® (spironolactone) Clinical Pharmacology | Pfizer Medical - US, accessed July 23, 2025, https://www.pfizermedical.com/aldactone/clinical-pharmacology
25. Role of spironolactone in the treatment of heart failure with preserved ejection fraction, accessed July 23, 2025, https://atm.amegroups.org/article/view/22398/21994
26. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis - PubMed, accessed July 23, 2025, https://pubmed.ncbi.nlm.nih.gov/15947888/
27. Antiandrogenic effect of spirolactones: mechanism of action - PubMed, accessed July 23, 2025, https://pubmed.ncbi.nlm.nih.gov/166833/
28. Pharmacodynamics of spironolactone - Wikipedia, accessed July 23, 2025, https://en.wikipedia.org/wiki/Pharmacodynamics_of_spironolactone
29. Spironolactone - American Osteopathic College of Dermatology (AOCD), accessed July 23, 2025, https://www.aocd.org/?page=Spironolactone
30. Showing BioInteractions for Spironolactone (DB00421) | DrugBank Online, accessed July 23, 2025, https://go.drugbank.com/drugs/DB00421/biointeractions
31. Use of spironolactone in treatment of hirsutism - Cleveland Clinic ..., accessed July 23, 2025, https://www.ccjm.org/content/ccjom/57/3/285.full.pdf
32. Treatment of hirsutism with spironolactone - PubMed, accessed July 23, 2025, https://pubmed.ncbi.nlm.nih.gov/7199587/
33. 13 Possible Side Effects of Spironolactone - GoodRx, accessed July 23, 2025, https://www.goodrx.com/spironolactone/common-serious-side-effects
34. spironolactone, accessed July 23, 2025, https://m.glowm.com/resources/glowm/cd/pages/drugs/s023.html
35. highlights of prescribing information - Pfizer, accessed July 23, 2025, https://labeling.pfizer.com/showlabeling.aspx?id=520
36. boxed warning - DailyMed, accessed July 23, 2025, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=50d3dfb4-c679-1a3f-e054-00144ff88e88&type=display
37. Spironolactone - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf, accessed July 23, 2025, https://www.ncbi.nlm.nih.gov/books/NBK501101/
38. Spironolactone - Deranged Physiology, accessed July 23, 2025, https://derangedphysiology.com/main/pharmacopeia/spironolactone
39. Spironolactone (oral route) - Side effects & dosage - Mayo Clinic, accessed July 23, 2025, https://www.mayoclinic.org/drugs-supplements/spironolactone-oral-route/description/drg-20071534
40. Spironolactone in Left-Sided Heart Failure: How Does It Fit In? - AAFP, accessed July 23, 2025, https://www.aafp.org/pubs/afp/issues/2001/1015/p1393.html
41. Spironolactone, a blood pressure medication, may help reduce risk of new heart failure, accessed July 23, 2025, https://newsroom.heart.org/news/spironolactone-a-blood-pressure-medication-may-help-reduce-risk-of-new-heart-failure
42. newsroom.heart.org, accessed July 23, 2025, https://newsroom.heart.org/news/spironolactone-a-blood-pressure-medication-may-help-reduce-risk-of-new-heart-failure#:~:text=November%2017%2C%202024-,Spironolactone%2C%20a%20blood%20pressure%20medication%2C%20may%20help%20reduce,risk%20of%20new%20heart%20failure&text=Research%20Highlights%3A,new%20heart%20attack%20or%20stroke.
43. Spironolactone Reduces the Risk of Death in Veterans With Heart Failure With Preserved Ejection Fraction, accessed July 23, 2025, https://www.ahajournals.org/doi/10.1161/JAHA.123.032231
44. Spironolactone: uses, dosing, warnings, adverse events, interactions - MedCentral, accessed July 23, 2025, https://www.medcentral.com/drugs/monograph/6288-382627/spironolactone-oral
45. www.nhs.uk, accessed July 23, 2025, https://www.nhs.uk/medicines/spironolactone/about-spironolactone/#:~:text=Spironolactone%20is%20used%20to%20treat,your%20pee%2C%20called%20nephrotic%20syndrome
46. Spironolactone for Edema Reviews - Drugs.com, accessed July 23, 2025, https://www.drugs.com/comments/spironolactone/for-edema.html
47. go.drugbank.com, accessed July 23, 2025, https://go.drugbank.com/drugs/DB00421#:~:text=Off%2Dlabel%20uses%20of%20spironolactone,loss%2C%20and%20adult%20acne%20vulgaris.
48. [Spironolactone in dermatological treatment. On and off label indications] - PubMed, accessed July 23, 2025, https://pubmed.ncbi.nlm.nih.gov/24150826/
49. Off label, on point | AAD, accessed July 23, 2025, https://www.aadmeetingnews.org/2024-aad-annual-meeting/article/22888730/off-label-on-point
50. Stubborn acne? Hormonal therapy may help, accessed July 23, 2025, https://www.aad.org/public/diseases/acne/derm-treat/hormonal-therapy
51. Should I Take Spironolactone for Acne? - Cleveland Clinic Health Essentials, accessed July 23, 2025, https://health.clevelandclinic.org/spironolactone-for-acne
52. Spironolactone for hormonal acne - Midland Skin, accessed July 23, 2025, https://www.midlandskin.co.uk/treatments/spironolactone-acne/
53. Spironolactone for Acne: Side Effects, Treatment, Dosage, and More - GoodRx, accessed July 23, 2025, https://www.goodrx.com/spironolactone/spironolactone-for-acne-how-does-it-work
54. emedicine.medscape.com, accessed July 23, 2025, https://emedicine.medscape.com/article/121038-treatment#:~:text=Spironolactone%3A%20Spironolactone%2C%20in%20daily%20doses,drug%20is%20a%20mild%20diuretic.
55. Is spironolactone (an antiandrogen medication) a suitable treatment option for a 25-year-old female patient with hirsutism (excessive hair growth), normal testosterone levels, and normal Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) levels? - Dr.Oracle AI, accessed July 23, 2025, https://www.droracle.ai/articles/106868/updates-about-using-of-spironolactone-in-treatment-of-hairsutism-in-female-patient-aged-25-years-old-and-had-normal-testosterone-level-normal-lh-fsh-is-spironolactone-is-good-option-for-such-cases-
56. Hirsutism - Diagnosis & treatment - Mayo Clinic, accessed July 23, 2025, https://www.mayoclinic.org/diseases-conditions/hirsutism/diagnosis-treatment/drc-20354941
57. xyonhealth.com, accessed July 23, 2025, https://xyonhealth.com/blogs/library/spironolactone-for-pcos#:~:text=How%20does%20spironolactone%20help%20with,et%20al.%2C%202022)..&sa=D&source=editors&ust=1753248546304984&usg=AOvVaw3qISJQtQBKKSSPg0biWpX5)
58. Spironolactone for PCOS | How It Works and Safety - XYON, accessed July 23, 2025, https://xyonhealth.com/blogs/library/spironolactone-for-pcos
59. Spironolactone's Role In Treating PCOS - HealthMatch, accessed July 23, 2025, https://healthmatch.io/pcos/spironolactone-for-pcos
60. Polycystic ovary syndrome (PCOS) - Diagnosis and treatment - Mayo Clinic, accessed July 23, 2025, https://www.mayoclinic.org/diseases-conditions/pcos/diagnosis-treatment/drc-20353443
61. Diagnosis and Treatment of Polycystic Ovary Syndrome - AAFP, accessed July 23, 2025, https://www.aafp.org/pubs/afp/issues/2016/0715/p106.html
62. How and when to take spironolactone - NHS, accessed July 23, 2025, https://www.nhs.uk/medicines/spironolactone/how-and-when-to-take-spironolactone/
63. Spironolactone Dosage: Forms, Strengths, How to Take, and More - Healthline, accessed July 23, 2025, https://www.healthline.com/health/drugs/spironolactone-dosage
64. Spironolactone oral tablet dosage: A detailed guide - Optum Perks, accessed July 23, 2025, https://perks.optum.com/blog/spironolactone-tablet-dosage
65. Spironolactone for Acne: Practical Strategies for Optimal Clinical ..., accessed July 23, 2025, https://www.mdedge.com/cutis/article/272626/acne/spironolactone-acne-practical-strategies-optimal-clinical-outcomes
66. What is the starting dose of spironolactone (aldosterone antagonist) for acne treatment?, accessed July 23, 2025, https://www.droracle.ai/articles/95447/starting-dose-of-spironolactone-for-acne
67. What is the recommended dose of spironolactone (aldosterone antagonist) for the treatment of acne? - Dr.Oracle AI, accessed July 23, 2025, https://www.droracle.ai/articles/127353/what-dose-of-spironolactone-for-acne
68. What is the appropriate dosing of Spironolactone for a 15-year-old patient with Polycystic Ovary Syndrome (PCOS)? - Dr.Oracle AI, accessed July 23, 2025, https://www.droracle.ai/articles/896/pcos-15yo-dosing-for-spironolactone
69. Spironolactone for PCOS Symptoms | Children's Hospital Colorado, accessed July 23, 2025, https://www.childrenscolorado.org/globalassets/departments/gynecology/informational-pdfs/options-for-managing-pcos-symptoms-spironolactone.pdf?v=490a4c
70. How Does Spironolactone Help Treat PCOS? | Ro, accessed July 23, 2025, https://ro.co/fertility/spironolactone-pcos/
71. Side effects of spironolactone - NHS, accessed July 23, 2025, https://www.nhs.uk/medicines/spironolactone/side-effects-of-spironolactone/
72. www.nhs.uk, accessed July 23, 2025, https://www.nhs.uk/medicines/spironolactone/side-effects-of-spironolactone/#:~:text=Serious%20side%20effects&text=you%20get%20a%20slow%20or,can%20be%20signs%20of%20dehydration
73. Aldactazide spironolactone and hydrochlorothiazide tablets WARNING Spironolactone, an ingredient of ALDACTAZIDE, has been shown - accessdata.fda.gov, accessed July 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/012616s075lbl.pdf
74. Pregnancy, breastfeeding and fertility while taking spironolactone - NHS, accessed July 23, 2025, https://www.nhs.uk/medicines/spironolactone/pregnancy-breastfeeding-and-fertility-while-taking-spironolactone/
75. Spironolactone: Pediatric Medication | Memorial Sloan Kettering Cancer Center, accessed July 23, 2025, https://www.mskcc.org/cancer-care/patient-education/medications/pediatric/spironolactone
76. ALDACTONE® (spironolactone) Contraindications | Pfizer Medical - US, accessed July 23, 2025, https://www.pfizermedical.com/aldactone/contradictions
77. Aldactone 25 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC) - (emc), accessed July 23, 2025, https://www.medicines.org.uk/emc/product/1619/smpc
78. Spironolactone - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Renal Dose, Hepatic Dose | Drug Index | Pediatric Oncall, accessed July 23, 2025, https://www.pediatriconcall.com/drugs/spironolactone/961
79. Taking spironolactone with other medicines and herbal supplements - NHS, accessed July 23, 2025, https://www.nhs.uk/medicines/spironolactone/taking-spironolactone-with-other-medicines-and-herbal-supplements/
80. Spironolactone and Interactions: Supplements, Alcohol, and More - Healthline, accessed July 23, 2025, https://www.healthline.com/health/drugs/spironolactone-oral-tablet-interactions
81. Spironolactone Interactions - Drugs.com, accessed July 23, 2025, https://www.drugs.com/drug-interactions/spironolactone.html
82. Aldactone Interactions Checker - Drugs.com, accessed July 23, 2025, https://www.drugs.com/drug-interactions/spironolactone,aldactone.html
83. 4 foods to avoid while taking spironolactone - SingleCare, accessed July 23, 2025, https://www.singlecare.com/blog/foods-to-avoid-while-taking-spironolactone/
84. Common questions about spironolactone - NHS, accessed July 23, 2025, https://www.nhs.uk/medicines/spironolactone/common-questions-about-spironolactone/
85. www.nhs.uk, accessed July 23, 2025, https://www.nhs.uk/medicines/spironolactone/common-questions-about-spironolactone/#:~:text=Do%20not%20have%20low%2Dsodium,%2C%20pulses%2C%20nuts%20and%20salmon.
86. Age-Related Divergence of Risk-Benefit Relationship of Spironolactone Treatment for Heart Failure With Preserved Ejection Fraction∗ | JACC, accessed July 23, 2025, https://www.jacc.org/doi/10.1016/j.jchf.2019.09.006
87. www.mayoclinic.org, accessed July 23, 2025, https://www.mayoclinic.org/drugs-supplements/spironolactone-oral-route/description/drg-20071534#:~:text=Appropriate%20studies%20performed%20to%20date,caution%20for%20patients%20receiving%20spironolactone.
88. Spironolactone | Drug Lookup | Pediatric Care Online - AAP Publications, accessed July 23, 2025, https://publications.aap.org/pediatriccare/drug-monograph/18/5810/Spironolactone
89. Spironolactone (Aldactone) - Children's Minnesota, accessed July 23, 2025, https://www.childrensmn.org/educationmaterials/childrensmn/article/15712/spironolactone-aldactone/
90. Spironolactone Precautions, accessed July 23, 2025, https://www.ttuhsc.edu/medicine/dermatology/documents/Spironolactone_Precautions.pdf
91. Human medicines European public assessment report (EPAR): Qaialdo, spironolactone, Date of authorisation: 26/05/2023, Revision: 1, Status, accessed July 23, 2025, https://efim.org/node/145769
92. Qaialdo | European Medicines Agency (EMA), accessed July 23, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/qaialdo
93. Spironolactone Ceva - EMA, accessed July 23, 2025, https://www.ema.europa.eu/en/documents/product-information/spironolactone-ceva-epar-product-information_en.pdf
94. Spironolactone (International database) - Drugs.com, accessed July 23, 2025, https://www.drugs.com/international/spironolactone.html
95. Spironolactone - brand name list from Drugs.com, accessed July 23, 2025, https://www.drugs.com/ingredient/spironolactone.html
96. Aldactone (Spironolactone) - PharmaServe Canada, accessed July 23, 2025, https://pharmaserve.com/pharmacy_drugs/aldactone-spironolactone/
97. Spironolactone - Guide to Brand or Trade Names - Medindia, accessed July 23, 2025, https://www.medindia.net/drugs/trade-names/spironolactone.htm